Abstract
Various mechanisms of epithelial cell plasticity in morphogenesis have been studied at the genetic and molecular levels. Several control genes have been identified including genes encoding transcription factors and growth factor receptors. These mechanisms may be reactivated during the progression of carcinomas. One of the mechanisms underlying epithelial plasticity is the epithelial–mesenchymal transition. This process has been extensively studied using the NBT-II bladder carcinoma cell line. Cells of this line undergo a reversible transition following exposure to several growth factors including FGF1, EGF, TGFα and SF/HGF, which activate tyrosine kinase surface receptors. Two separate transduction pathways have been identified. The transient activation of c-Src is involved in cytoskeleton remodeling whereas the Ras pathway controls the transcription of genes such as the transcription factor Slug which is involved in the internalization of desmosomes. These two pathways cooperate to induce the morphological transition, scattering and locomotion of fibroblast-like cells. Growth/scatter factor-producing NBT-II cells are more invasive than cells that do not contain this factor, in orthotopic confrontation assay. In vivo, these cells are very tumorigenic and may confer a more malignant phenotype on parental cells via a community effect. The role of several growth factors and their receptors has been investigated in human bladder carcinomas. A subset of these tumors with poor outcomes produce low levels of FGFR2-IIIb. The synthesis of this receptor de novo in bladder cell lines reduces proliferation in vitro and tumor growth in nude mice. FGFR2-IIIb functions as a tumor suppressor, consistent with the differentiation-inducing capacities of FGF receptors in the suprabasal cells of the skin. FGFR2-IIIb signaling may be involved in the maintenance of E-cadherin, the prototype epithelial adhesion molecule, which is only downregulated in a fraction of tumors with low FGFR2-IIIb synthesis. Human bladder tumors may also activate autocrine loops such as that for EGFR and their ligands, as already demonstrated for murine bladder tumors. Therefore, our results suggest that multifunctional growth factors and their receptors are involved in cell proliferation and epithelial cell plasticity, acting either as positive or negative regulators of tumor progression. The effect on the morphological transition is also clearly relevant to the mechanism governing dissemination and the formation of micrometastatic tumor cells. The extrapolation of these discoveries to human carcinomas should provide markers facilitating the more accurate prediction of the biological behavior of a given tumor and identify clinically and pathologically significant parameters. The identification of critical changes in the growth factor pathways involved in tumor progression will not only provide insight into the genetic and molecular basis of this process, but should also identify targets for new therapies.
Similar content being viewed by others
References
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 396: 643–649, 1998
Shackney SE, Shankey TV: Common patterns of genetic evolution in human solid tumors. Cytometry 29: 1–27, 1997
Fagnou C, Michon J, Peter M, Oberlin O, Zucker JM, Magdelenat H, Delattre O: Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. J Clin Invest 16: 1707–1711, 1998
Thibodeau SN, Bren G, Shaid D: Micro satellite instability in cancer of the proximal colon. Science 260: 816–819, 1993
Lothe A, Peltomäki P, Meling GI, Aaltonen LA, Nyström-Lahti M et al.: Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53: 5849–5852, 1993
Kochhar R, Hailing KC, McDonnell S, Shaid DJ, French AM, O'Connell MJ, Nagorney DM, Thibodeau SN: Allelic imbalance and microsatellite instability in resected Duke's colorectal cancer. Diagnost Mol Pathol 6: 78–84, 1997
Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Binbaum EH, Read TE, Fleshman JW, Kodner IJ, Moley JF: Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Onc 16: 427–433, 1998
Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR: Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 114: 1188–1195, 1998
Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534–2539, 1996
Fox SB: Tumor angiogenesis and prognosis. Histopathology 30: 294–301, 1997
Viens P, Pernault-Llorca F, Jacquemier J, Gravis C, Cowen D, Bertucci F, Houvenaeghel G, Blaise D, Maraninchi D: High dose chemotherapy and haematopoietic stem cell transplantation for inflammmatory breast cancer: pathologic response and outcome. Bone Marrow Transplantation 21: 249–254, 1998
Kinzler KW, Vogelstein B: Landscaping the cancer terrain. Science 280: 1036–1037, 1998
Watson KL, Justice RW, Bryant P: Drosophila in cancer research: the first fifty tumor suppressor genes. Development 18: 19–33, 1994
Gilbert SF: Developmental Biology. Fifth edition. Massachusetts Sinauer Associates Inc. Publishers, Sunderland, 1997
Jouanneau J, Tucker GC, Boyer B, Valleś AM, Thiery JP: Epithelial cell plasticity in neoplasia. Cancer Cells 3: 525–529, 1991
Savagner P, Boyer B, Valles AM, Jouanneau J, Thiery IP: Modulations of the epithelial phenotype during embryogenesis and cancer progression. In: Dickson R, Lipmann M (eds) Mammary tumorigenesis and malignant progression. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1994, pp 229–249
Birchmeier C, Birchmeier W, Brand-Saberi B: Epithelial-mesenchymal transitions in cancer progression. Acta Anat 156: 217–226, 1996
Leptin M, Casal J, Grunewald B, Reuter R: Mechanisms of early Drosophila mesoderm formation. In: Stern CD, Ingham PW (eds) Gastrulation. The Company of Biologists, 1992, pp 23–31
Morize P, Christiansen AE, Costa M, Parks S, Wieschaus E: Hyperactivation of the folded gastrulation pathway induces specific cell shape changes. Development 125: 589–597, 1998
Hacker U, Perrimon N: DRhoGEF2 encodes a member of the Dbl family of oncogenes and controls cell shape changes during gastrulation in Drosophila. Genes & Development 12: 274–284, 1998
Keller R: Early embryonic development of Xenopus laevis. In: Kay KB, Peng BH (eds) Methods in Cell Biology. Xenopus laevis: practical uses in Cell and Molecular Biology. Academic Press, 1991, pp 61–113
Niehrs C, Keller R, Cho KWY, De Robertis EM: The homeobox gene goosecoid controls cell migration in xenopus embryos. Cell 72: 491–503, 1993
Pannese M, Polo C, Andreazzoli M, Vignali R, Kablar B, Barsacchi G, Boncinelli E: The Xenopus homologue of Otx2 is a maternal homeobox gene that demarcates and specifies anterior body regions. Development 121: 707–720, 1995
Broders F, Thiery JP: Contribution of cadherins to directional cell migration and histogenesis in xenopus embryos. Cell Adh Com 3: 419–440, 1995
Kim S-H, Yamamoto A, Bouwmeester T, Agius E, De Robertis EM: The role of paraxial protocadherin in selective adhesion and cell movements of the mesoderm during Xenopus gastrulation. Development 125: 4681–4691, 1998
Le Douarin N: The Neural Crest. Cambridge University Press, 1982.
Thiery JP, Duband JL, Dufour S: Adhesion systems in morphogenesis and cell migration during avian embryogenesis. In: Morphoregulatory Molecules. John Wiley and Sons, New York, 1990, pp 597–625
Duband JL, Monier F, Delannet M, Newgreen D: Epithelium-mesenchyme transition during neural crest development. Acta Anat 154: 63–78, 1996
Nieto AM, Sargent MC, Wilkinson DG, Cooke J: Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 264: 835–839, 1994
Mancilla A, Mayor R: Neural crest formation in Xenopus laevis: mechanisms of Xslug induction. Dev Biol 177: 580–589, 1996
Glazer L, Shilo B-Z: The Drosophila FGF-R homolog is expressed in the embryonic tracheal system and appears to be required for directed tracheal cell expension. Gene Dev 5: 697–705, 1991
Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow D: Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92: 253–263, 1998
Bellusci S, Grindley J, Emoto H, Itoh N, Hogan BL: Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development 124: 4867–4878, 1997
Peters K, Werner S, Liao X, Wert S, Whitsett J, Williams L: Targeted expression of a dominant negative FGF receptor blocks branching morphogenesis and epithelial differentiation of the mouse lung. EMBO J 13: 3296–3301, 1994
Niemann C, Brinkmann V, Spitzer E, Hartmann G, Sachs M, Naundorf H, Birchmeier W: Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol 143: 533–545, 1998
Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM: Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285–288, 1998
Tchao R: Novel forms of epithelial cell motility on collagen and on glass surfaces. Cell Motil 4: 333–341, 1982
Boyer B, Tucker GC, Vallés AM, Gavrilovic J, Thiery JP: Reversible transition towards a fibroblastic phenotype in a rat carcinoma cell line. Int J Cancer 4: 69–75, 1989
Vallés AM, Tucker G, Thiery JP, Boyer B: Alternative patterns of mitogenesis and cell scattering induced by acidic FGF as a function of cell density in a rat bladder carcinoma cell line. Cell Regulation 4: 975–988, 1990
Vallés AM, Boyer B, Tucker GC, Badet J, Barritault D, Thiery JP: Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc Natl Acad Sci USA 87: 1124–1128, 1990
Gavrilovic J, Moens G, Thiery JP, Jouanneau J: Expression of TGFα induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell Regulation 1: 1003–1014, 1990
Bellusci S, Moens G, Gaudino G, Comoglio P, Nakamura T, Thiery JP, Jouanneau J: Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased oncogenic potential. Oncogene 9: 1091–1099, 1994
Boyer B, Valles AM, Thiery JP: Model systems of epithelium-mesenchyme transition. Acta Anat 156: 227–239, 1996
Savagner P, Vallés AM, Jouanneau J, Yamada K, Thiery JP: Alternative splicing in Fibroblast Growth Factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 5: 851–862, 1994
Boyer B, Dufour S, Thiery JP: E-cadherin expression during the acidic FGF-induced dispersion of a rat bladder carcinoma cell line. Exp Cell Res 201: 347–357, 1992
Boyer B, Thiery JP: Cyclic AMP Distinguishes between two functions of acidic FGF in a rat bladder carcinoma cell line. J Cell Biol 120: 767–776, 1993
Rodier JM, Valles AM, Denoyelle M, Thiery JP, Boyer B: pp60c-Src is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line. J Cell Biol 131: 761–773, 1995
Boyer B, Roche S, Denoyelle M, Thiery JP: Src and ras are involved in separate pathways in epithelial cell scattering. EMBO J 16: 5904–5943, 1997
Savagner P, Yamada KM, Thiery JP: The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol 137: 1403–1419, 1997
Tucker GC, Delouvée A, Jouanneau J, Gavrilovic J, Moens G, Vallés AM, Thiery JP: Amplification of invasiveness in organotypic cultures after NBT-II rat bladder carcinoma stimulation with in vitro scattering factors. Cell Adh Com 11: 297–309, 1991
Jouanneau J, Moens G, Bourgeois Y, Poupon MF, Thiery JP: A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. Proc Natl Acad Sci USA 91: 286–290, 1994
Gurdon JB, Lemaire P, Kato K: Community effects in related phenomena in development. Cell 75: 831–834, 1993
Jouanneau J, Plouet J, Moens G, Thiery JP: FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo. Oncogene 14: 671–676, 1997
Bellusci S, Moens G, Thiery JP, Jouanneau J: A scatter factor-like factor is produced by a metastatic variant of a bladder carcinoma line. J Cell Science 107: 1277–1287, 1994
Aaronson SA: Growth factors and cancer. Science 254: 1146–1152, 1991
Fan Z, Mendelsohn J: Therapeutic application of antigrowth factor receptor antibodies. Curr Op Oncology 10: 67–73, 1998
Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J: Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 48: 2083–2088, 1988
Chopin DK, Caruelle JP, Colombel M, Palcy S, Ravery V, Caruelle D, Abbou C, Barritault D: Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 150: 1126–1130, 1993
Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85: 241–242, 1993
Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independance and malignancy. Mol Cell Biol 13: 4513–4522, 1993
Yamaguchi F, Saya H, Bruner JM, Morrison RS: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91: 484–488, 1994
Nakagawara A, Arima-Nakagawara M, Azar CG, Scavarda NJ, Brodeur GM: Clinical significance of expression of neurotrophic factors and their receptors in neuroblastoma. Progress of clinical and biological research 385: 155–161, 1994
Kim IY, Ahn HJ, Lang S, Oefelein MG, Osyasu R, Kolowski KM, Lee C: Loss of expression of transforming growth factor beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 4: 1625–1630, 1998
Werner S, Weinberg W, Liao X, Peters KG, Blessing M, Yuspa SH, Weiner RL, Williams LT: Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals arole of FGF in keratinocyte organization and differentiation. EMBO J 12: 2635–2643, 1993
Werner S, Smola H, Liao X, Longaker MT, Krieg T, Hofschneider PH, Williams LT: The function of KGF in morphogenesis of epithelium and reepitheliasation of wounds. Science 266: 819–822, 1994
Itoh H, Hattori Y, Sakamoto H, Ishii H, Kishi T, Sasaki H, Yoshida T, Koono M, Sugimura T, Terada M: Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res 54: 3237–3241, 1994
Chesi M et al.: Frequent translocation t(4;14)(p16.3; q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 16: 260–264, 1997
Ornitz DM, Leder P: Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J Biol Chem 267: 16305–16311, 1992
Kanai M, Goke M, Tsunekawa S, Podolsky D: Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of anovel 66-kDaphosphoprotein. J Biol Chem 272: 6621–6628, 1997
Naski MC, Wang Q, Xu J, Ornitz DM: Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet 13: 233–237, 1996
Webster M, D'Avis PY, Robertson SC, Donhogue DJ: Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16: 4081–4087, 1996a
Webster M, Donhogue DJ: Consitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain mutation found in achondroplasia. EMBO J 15: 520–527, 1996b
Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM: Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet 12: 390–397, 1996
Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P: Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84: 911–921, 1996
Ricol D, Cappellen D, El Marjou A, Gil-Diez de Medina S, Girault J-M, Ferry G, Tucker G, Poupon M-F, Chopin D, Thiery JP, Radvanyi F: Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene (in press) 1999
Birchmeier W, Behrens J: Cadherin expression in carcinomas: role in the formation of cell junction and the prevention of invasiveness. Biochem Biophys Acta 1198: 11–26, 1994
Gil-Diez de Medina S, Popov Z, Chopin DK, Southgate J, Tucker G, Delouvée A, Thiery JP, Radvanyi F: Relationship between E-cadherin and Fibroblast Growth Factor Receptor 2b expression in bladder carcinomas. Oncogene (in press) 1999
Schmidt L et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet 16: 68–73, 1997
Kolibaba KS, Druker BJ: Protein tyrosine kinases and cancer. Biochimica et Biophysica Acta 1333: 217–248, 1997
Ravery V, Colombel M, Popov Z, Bastuji S, Patard JJ, Bellot J, Abbou CC, Fradet Y, Chopin DK: Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 71: 196–200, 1995
Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M: Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 53: 4741–4744, 1993
Jacquemier J, Adelaide J, Parc P, Penault-Llorca F, Planche J, DeLapeyriere O, Birnbaum D: Expression of the FGFR1 gene in human breast carcinoma cells. Int J Cancer 59: 373–378, 1994
Xiao S et al.: FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genet 18: 84–87, 1998
Feng S, Wang F, Matsubara A, Kan M, McKeehan WL: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 57: 5369–5378, 1997
El Marjou A, Delouvee A, Thiery JP, Radvanyi F: A positive autocrine loop EGF-R/ligands is involved in chemically-inducedmousebladder tumourprogression. Submitted 1999
Boyer B, Thiery JP: Epithelium-mesenchyme interconversion as example of epithelial plasticity. Apmis 101: 257–268, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thiery, J.P., Chopin, D. Epithelial Cell Plasticity in Development and Tumor Progression. Cancer Metastasis Rev 18, 31–42 (1999). https://doi.org/10.1023/A:1006256219004
Issue Date:
DOI: https://doi.org/10.1023/A:1006256219004